Related Experiment Video
Updated: Sep 18, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors
Haiting Xu1, Chenghui Wang2, Bo Xiao3
1State Key Laboratory of Resource Insects, College of Sericulture, Textile, and Biomass Sciences, Southwest University, Chongqing 400715, China.
Abstract:
Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod primes plasmacytoid dendritic cells (DCs) to produce type I interferon, thereby sensitizing conventional DCs in tumors to local Toll-like receptor 7 activation. This approach triggers c-Jun-dependent IL-12 production and CCL2-mediated plasmacytoid DC recruitment, enabling localized and systemic tumor suppression. Importantly, the therapy synergizes with PD-1 blockade to prevent recurrence, representing a significant advance in DC-targeted cancer immunotherapy.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The Tumor Microenvironment
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

